SecBot SecBot
SECBOTREPLAY Home › Report › COLL

COLL · Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD…

Collegium Pharmaceutical, Inc. · PRESS-RELEASE filed May 12, 2026 at 07:31 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 12, 2026 at 07:31 ET

Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for $650 million in cash, funded by existing cash and a new term loan. The company raised its 2026 guidance to reflect the deal, now expecting product revenues of $865-$895 million and adjusted EBITDA of $475-$500 million. The acquisition is expected to be immediately accretive and extends Collegium's revenue outlook with patent protection through 2037.

  • Acquired AZSTARYS for $650 million in cash, funded by $350 million cash on hand and $300 million from a delayed draw term loan.
  • Up to $135 million in additional milestone payments possible.
  • AZSTARYS generated over 760,000 prescriptions in 2025; expected to contribute $60-$70 million in net revenue in H2 2026.
  • 2026 guidance raised: product revenues $865-$895 million (from $805-$825 million); adjusted EBITDA $475-$500 million (from $455-$475 million).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access